Prospective study with patients who have undergone surgery for stage II or III CRC and who receive Signatera testing. Treating clinicians may recommend adjuvant chemotherapy or observation based on test results. BESPOKE CRC is expected to be active at more than 50 sites around the US and is still open to initiate new sites.
United States, California Stockton Hematology Oncology Medical Group, Stockton, California, United States, 95204 Contact: Ajithkumar Puthillath, MD, (209) 466-2626
United States, Florida Oncology & Hematology Associates of West Broward, Tamarac, Florida, United States, 33321 Contact: Sumit Sawhney, MD, (954) 726-0035
United States, Indiana Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana, United States, 46804 Contact: Ahad Sadiq, MD, (260) 436-0800
United States, Louisiana Pontchartrain Cancer Center, Covington, Louisiana, United States, 70433 Contact: David Oubre, MD, (985) 875-1202
United States, New Jersey New Jersey Cancer Care, Belleville, New Jersey, United States, 07109 Contact: James Orsini, MD, (973) 751-8880
United States, Ohio The Toledo Clinic, Toledo, Ohio, United States, 43623 Contact: Rex Mowat, MD, (419) 473-3561
United States, Oklahoma Oklahoma Cancer Specialists and Research Institute, Tulsa, Oklahoma, United States, 74146 Contact: Byron Jennings, MD
United States, Oregon Oregon Oncology Specialists, Salem, Oregon, United States, 97301 Contact: Janelle Meyer, MD, (918) 505-3200
United States, South Carolina Carolina Blood and Cancer Care Associates, Rock Hill, South Carolina, United States, 29732 Contact: Niyati Nathwani, MD, (803) 329-7772
United States, Virginia Virginia Cancer Institute, Richmond, Virginia, United States, 23226 Contact: Nathan Langer, MD, (804) 673-0134
United States, Washington Summit Cancer Centers, Spokane, Washington, United States, 99208 Contact: Arvind Chaudhry, MD, (855) 786-6482 Northwest Medical, Tacoma, Washington, United States, 98405 Contact: Jorge Chaves, MD, (253) 428-8700